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Dendritic cell therapy has been a promising addition to the current armory of ther-
apeutic options in cancer for more than 20 years but has not yet achieved break-
through success. To successfully initiate immunity, dendritic cells have to enter the
lymph nodes. However, experience to date of therapeutic dendritic cell administra-
tion indicates that this is frequently an extremely inefficient process. The major regu-
lator of dendritic cell migration to the lymph nodes is the chemokine receptor CCR7
and in vitro generated dendritic cells typically display heterogeneous expression of
this receptor. Here we demonstrate that positive selection for the dendritic cell sub-
population expressing CCR7, using a chemically-synthesized ligand:CCL19, enriches
for cells with enhanced lymph node migration and Ag presentation competence as
well as a chemokine expression profile indicative of improved interactions with T cells.
This enhanced lymph node homing capacity of enriched CCR7+ cells is seen in com-
parison to a population of unsorted dendritic cells containing an equivalent number
of CCR7+ dendritic cells. Importantly, this indicates that separating the CCR7+ den-
dritic cells from the CCR7− cells, rather than simple CCL19 exposure, is required to
affect the enhanced lymph node migration of the CCR7+ cells. In models of both sub-
cutaneous and metastatic melanoma, we demonstrate that the dendritic cells sorted
for CCR7 expression trigger enhancedCD8T-cell driven antitumor immune responses
which correlatewith reduced tumor burden and increased survival. Finally, we demon-
strate that this approach is directly translatable to human dendritic cell therapy using
the same reagents coupled with clinical-grade flow-cytometric sorting.
KEYWORDS
cancer, chemokines, translation, vaccines, cellular therapy
1 INTRODUCTION
Cellular therapy is an increasingly important treatment option in a
range of clinical contexts including cancers and inflammatory/immune
disorders.1–3 However, success is often limited by the mixed ability of
the cells to home to, or be retained in, appropriate in vivo “therapeutic”
sites. In the context of dendritic cell (DC) therapy the limited compe-
tence of therapeutically administered DCs to home to lymph nodes
(LNs) from the injection site4–6 has contributed to a marked ineffi-
ciency of this therapeutic approach. Despite attempts to improve this,
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insufficient LN homing remains a frequent impairment to effective DC
therapy. New approaches are therefore urgently needed to optimize
such cell therapies.
Chemokines are central to in vivo tissue-homing of cells7 and
humans have approximately 45 chemokines many of which are
expressed at select in vivo sites, or in specific inflamed contexts.
Chemokines arebroadly characterized asbeing inflammatoryor home-
ostatic according to the in vivo contexts in which they function.
The selective nature of chemokine expression ensures the attraction
of cells bearing appropriate cognate chemokine receptors8 to spe-
cific tissues. One of the classic paradigms for chemokine receptor
involvement in cellular homing focuses on CCR7,9 which is essen-
tial for cellular homing to, and positioning within, LNs.10 During DC
maturation, up-regulation of CCR79 ensures efficient LN migration to
facilitate communication with T cells. Overexpression of CCR7 in DCs
inmurinemodels hasbeenclearly linkedwith increasedLNhoming11,12
and in human cancer patients, the extent of CCR7 expression on DCs
correlates with the magnitude of the tumor-infiltrating lymphocyte
population.13 However, to date, attempts to increase LN homing com-
petence of cells, either by manipulating CCR7 expression or by other
means, have frequently been cumbersome and of limited applicability
to the clinical context.11,12,14–16
We have developed a novel approach to help address this issue.17
While DC populations generated in vitro for therapeutic purposes
invariably express heterogeneous levels of CCR7, we have shown that
selection of the subpopulation expressing CCR7 leads to a ‘fitter’ cel-
lular product with enhanced LN homing. Typically such cell-selection
would be carried out using Abs but high-quality Abs are not available
for themajority of chemokine receptors.We therefore use chemokines
labeled with biotin and/or fluorophores, rather than Abs, to select for
cognate receptor-expressing cells.17,18 Specifically for sorting CCR7-
expressing cells we use streptavidin-tetramerized biotinylated CCL19
(bCCL19).
Here, we have used models of primary and metastatic cancer to
show enhanced immune priming by CCR7-sorted DCs with improved
outcomes in the tumor models. This study demonstrates the value of
preselection of DCs for LN homing potential and highlights a poten-
tially important novel development for therapeutic approaches to DC
use in cancer vaccinology.
2 BRIEF MATERIALS AND METHODS
2.1 Animals
C57BL/6 mice were from Charles River Laboratories, and OT-I mice
were bred andmaintained in house. All experiments were approved by
the University of Glasgow Ethical Review Committee and performed
under the auspices of a UKHomeOffice Licence.
2.2 Isolation of mouse and human cells
Bone marrow-derived DCs (BMDCs) were generated as outlined in
SupplementaryMaterials AndMethods and as described previously.17
Murine T cells were isolated from harvested peripheral LNs of
8 week-old OT-I mice, by homogenizing LNs through a cell strainer,
and plated at 2 × 106 cells/ml in mRPMI until use. Human buffy coats
were obtained from SNBTS under appropriate sample governance
and CD14+ monocyte-derived DCs (moDCs) generated as described
previously17,26 and T cell populations cultured in vitro as described
in Supplementary Materials And Methods. BMDCs and moDCs were
sorted for CCR7 expression by labeling with biotinylated chemically
synthesized CCL19 (bCCL19, Almac Sciences, UK)17 as outlined in
Supplementary Materials And Methods, “Mock sorted” DCs were
processed in labeling buffer only, followed by cell sorting of the entire
population based on the same scatter gates as the bCCL19-labeled
cells. For some in vivo experiments, cells were labeled with the
bCCL19 reagent but not sorted into CCR7 enriched or depleted
fractions.
2.3 In vitro T cell stimulation
To assessDC stimulation of T cell responses, T cellswere co-cultured in
vitro with either CCR7-sorted or unsorted DCs, or 20 U/ml IL-2 alone,
at a ratio of 1:25 DCs:T cells in complete RPMI. Cultures were main-
tained for 7 days (mouse) or 10 days (human), with media replaced as
necessary.
2.4 Animal experiments: Footpad migration
BMDC cultures were mock sorted, or sorted into a CCR7+population.
Both populationswere labeled using PKH67dye (Sigma-Aldrich) as per
the manufacturer’s guidelines. Cells were injected into the contralat-
eral footpads ofmice and after 48h the draining popliteal LNs and foot-
pads were collected for enumeration of DCs in each tissue. A total of
106 CCR7+ sorted cells were injected. Themock-sorted cells were for-
mulated to contain a total of 106 CCR7+ cells tonormalize thenumbers
ofCCR7+ cells administered (typically a total of 1.5×106 cells). To ana-
lyze cells present in the footpad at 48 h, the tissue was digested using
2mg/ml Collagenase IV, 2mg/ml hyaluronidase, and 0.1mg/ml DNase I
(all Invitrogen) in RPMI for 20min at 37◦C.19
2.5 Animal experiments: Tumor models
To generate subcutaneous tumors, 8-week oldmalemicewere injected
on the right flank with 5 × 105 B16.ova cells.24 Tumors were allowed
to grow until any animal in the cohort carried a tumor of 12 mm in
diameter (commonly first reached in control groups), triggering a cull
of all subjects. The number of days to reach this point is detailed in each
experimental section. To generate metastatic tumors, 8-week old male
mice were injected intravenously with 5× 105 B16.ova cells and culled
after a set period of 14 days.24 All tumor experiments had at least 5
animals per group.
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F IGURE 1 CCR7-sorted dendritic cells are
enhanced for Ag presentation. (A) (i) BMDC
cultures are heterogeneous for CCR7
expression (FSC= Forward Scatter)
post-incubation with Ag, LPS, and TNF-α. (ii)
CCR7+ cells are amajority CD11c+ zbtb46+
population of DCs, CCR7− cells are amixed
population containing aminority CD11c and
zbtb46+ cells. (B) Expression of markers of
Ag-presenting competence and T cell
co-stimulation in CCR7− (grey bars) and
CCR7+ (red bars) cells (n= 4 separate
cultures). (C) CD44 and CD62L expression in T
cells exposed to ova-pulsed BM cell cultures
sorted into CCR7− and CCR7+ cells (n= 3
separate cultures). (D) Tissue location of
PKH-67-labeled DC populations 48 h
post-injection expressed as a percentage of all
viable cells recovered from the tissues.
Control= PBS only injection. Cells mock
sorted, but not fractioned, remain largely at
the footpad injection site, while
CCR7-selected cells have largely migrated to
the draining lymph node. The numbers of
CCR7+ cells in the non-sorted population were
equivalent to those in the sorted population.
(E) Analysis of DLN populations at date of cull
in subcutaneous B16.ova-tumour-bearing
mice treated with CCL19-reagent-exposed
BMDC cultures, mock sorted or CCR7+ sorted.
The CCR7+ sorted cells induced significantly
higher percentages of SIINFEKL tetramer+
CD8 T cells in the draining pLN compared to
PBS controls or the CCL19-exposed but
unsorted population (Ei). Both DC populations
induced significantly higher numbers of
memory T cells in the draining LN, but this
effect reached greater signficance using
CCR7+ sorted cells (Figure 1Eii). n= 6 or 7
mice per group. Data are presented asmean±
SEM error bars. Statistical analysis was by
one-way ANOVA (B,E), two-way ANOVA (C, D)
with Bonferroni’s Multiple Comparisons Test:
n.s. is not significant, *P< 0.05; **P< 0.01;
***P< 0.001; ****P< 0.0001
2.6 Statistical analyses
Data are presented as mean ± SEM. Statistical analyses were per-
formed using GraphPad Prism 5 and 9 (GraphPad Software, La Jolla,
CA, USA). Student’s t-test 2-tailed and one and two-way ANOVA
followed by Bonferroni’s multiple comparisons post-test were used
(details in figure legends). Tumor survival scores were assessed using
Log-Rank (Mantel-Cox) test. Differences were considered statistically
significantwhenP<0.05.P values<0.01 and<0.001are also reported
where appropriate.
3 RESULTS AND DISCUSSION
3.1 Phenotypic characterization of CCR7-sorted
DCs
BM in vitro cultures contained a majority F4/80- CD11c+ zbtb46+ DC
population. Expression of CCR7 was most prevalent in the CD11c+
zbtb46+ population. CCR7− cells included CD11c+zbtb46+, CD11c+
zbtb46-, and F4/80+ CD11c- cells. (Figure 1Ai). The CCR7+ popula-
tion thus represents a homogeneous population of DC,20 while the
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CCR7− population contains a mixture of DCs, Mϕs, and other myeloid
cells. CCR7+ cells were sorted from this mixed population using the
bCCL19-sorting strategy17 (Fig. 1Aii). Henceforth, we refer to 3 cellu-
lar populations: (i) mock sorted DCs; (ii) sorted DCs (cells enriched for
CCR7expression), and (iii) CCR7− cells (the cells left from theunsorted
population after removal of the CCR7+ cells).
Next, we examined the expression of conventional markers of DC
maturity on the sorted cells. In contrast to CCR7− cells, the sorted
CCR7+ cells expressedmarkedly higher levels ofMHCI, MHCII, CD40,
CD86, and CD80 (Fig. 1B) indicating increased competency for Ag pre-
sentation and T cell stimulation.We usedOT-I CD8+ T cells to examine
T-cell activating capacity of ova-pulsed CCR7+ and CCR7− cells. The
CCR7+ cells preferentially expanded a more mature CD44+CD62L-
effector/memory CD8+ T cell phenotype while the CCR7− supported
less mature CD44-CD62L- CD8+ T cell populations over the course of
7 days T cell expansion in vitro (Fig. 1Ci and ii).
CCR7− cells expressed detectable levels of a number of inflamma-
tory chemokines, while these were either not expressed, or expressed
at lower levels, by the sorted CCR7+ cells (Supplementary Fig. 1A).
In contrast, the CCR7+ DCs expressed elevated levels of chemokines
binding to CCR4 (CCL17 and CCL22) and CXCR6 (CXCL16)
(Supplementary Fig. 1B), which are involved in the attraction of
effector/memory T cell populations, as well as regulatory T cells.21,22
These data therefore suggest that, in contrast to their CCR7− counter-
parts, the CCR7+- sorted cells are more primed for development of a
protective adaptive immune response through the attraction of CD8+
and CD4+ T cells.
In keeping with roles for CCR7 in cell migration to LNs,9 the CCR7+
sorted DC populationmigrated very efficiently from the footpad injec-
tion site to the draining popliteal LN (pLN) (Fig. 1D). In contrast, the
mock-sorted population, containing an identical number of CCR7+
cells, migrated poorly (Fig. 1D). This indicates that sorting CCR7+ cells
to homogeneity confers a benefit, and the injection of mixed popula-
tions results in poor migration of DCs to the DLN irrespective of the
presence of a substantial number of CCR7+ cells.
Exposure of mixed cell populations to the bCCL19 reagent could
potentiate in vivo cell migration and initiation of immune reponses.
Cells were generated that had all been exposed to the bCCL19-
SAPE reagent, one part was sorted into CCR7+ cells, and the other
mock-sorted. These cells were injected into the footpad as before
(normalized to contain equal numbers of CCR7+ cells), and the mice
were challenged subcutaneously 24 h later with B16-OVA tumor
cells (23 and see the following section). We assayed the pheno-
type and Ag-specificity of T cells in the pLN draining the foot pad.
The CCR7+ cell population induced significantly higher percentages
of SIINFEKL tetramer+ CD8 T cells in the draining pLN compared
to saline controls, whereas CCL19-exposed but unsorted population
did not induce significantly more tetramer-positive cells than saline
alone (Fig. 1Ei.). Both DC populations induced significantly higher
numbers ofmemoryT cells in the draining LNcompared to saline alone,
which may suggest a positive DC priming role for CCL19 exposure,
but this effect reached greater significance using CCR7+ sorted cells
(Fig. 1Eii.).
Together, these data demonstrate that sorting for CCR7 enriches
a population of cells with enhanced LN homing and T cell activation
competence. Our data further indicate the CCR7− cells in the mixed
population exert a negative effect when co-injected with equivalent
numbers of CCR7+ cells. The positive effect of CCL19-based cell
purification cannot be replicated by simple incubation of themixedDC
population with CCL19.
3.2 Sorted DCs display enhanced antitumor
activity in vivo
Wenext tested the relative abilities of sorted, andmock-sorted, unfrac-
tioned, DCs to give rise to protective antitumor immune responses.
As a model system, we used the subcutaneous B16.ova melanoma
model23 which expresses ovalbumin as a tumor-specific neo-Ag.
Again, the number of CCR7+ cells in the unsorted population
injected into recipient mice was equivalent to the number of CCR7+
-sorted DCs. In this model (Supplementary Fig. 2A) ova-peptide pulsed
DCs were injected into the footpad 1 day before subcutaneous tumor
injection. Tumors developed for 17 days at which time all animals were
culled and tissue harvested for analysis. While the unsorted DCs did
not alter tumor development, the sorted DCs had a significant effect
on tumors with a 25% reduction in tumor size observable throughout
the course of the experiment (Figure 2A). No differences were noted
in time-to-initiation of tumor development. These data demonstrate
that, in the context of an aggressively growing neoantigen-expressing
tumor, sorted DCs are superior to unsorted DCs, containing a numer-
ical equivalence of CCR7+ cells, in mediating antitumor immune
responses.
As shown in Figure 2Bi, and in keeping with the enhanced LNmigra-
tion of DCs from the injection site, we found higher numbers of ova-
specific CD8+ T cells in the footpad-draining pLNs of mice receiving
sorted DCs compared to unsorted DCs. In contrast, we saw no dif-
ference in numbers of ova-specific CD8+ T cells in the non-draining
inguinal LNs (iLN) (Fig. 2Bii) thus the anti-ova response is specifically
increased in the LNs draining the DC injection site. Notably, in the
pLNs (Fig. 2Ci) there was a specific increase in the numbers of ova-
responsive naive and central memory CD8+ T cells. In contrast, there
was a reduction in central memory T cell numbers in the iLNs of mice
injected with both unsorted and sorted DCs (Fig. 2Cii).
Thesedatademonstrate thatCCR7-sortedDCshaveenhancedanti-
tumor activity compared to unsorted cells associated with improved
migration to draining LNs and induction of systemic central memory T
cell responses.
3.3 Double prophylactic administration of sorted
DCs enhances antitumor responses
Next, we examined whether 2 DC administrations amplified the
improvement seen after 1 DC injection (Supplementary Fig. 2B). These
experiments were not run over a set time course, rather tumors were
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F IGURE 2 CCR7-sorted dendritic cells trigger enhanced antitumor immune responses. (A) graph of subcutaneous tumor growth over the 17
days of the single dendritic cell injectionmodel. Black dots: PBS injectedmice; blue dots: unsorted (mock sorted) BMdendritic cell (uDC) injected
mice; red dots: CCR7+ dendritic cell (sDC) injectedmice (n= 5; *P< 0.05 for sDC to both PBS and uDC groups). (B) Numbers of ova-tetramer+
CD8 T cells in the (i) injection site draining popliteal (pLN) and (ii) tumor-draining inguinal lymph nodes (iLN). (n= 5; data points represent
individuals). (C) phenotypic characterization of T cell populations in the (i) draining popliteal and (ii) non-draining iLNs. Black bars: PBS injected
mice; blue bars: uDC injectedmice; red bars: sDC injectedmice (n= 5). (D) Graph of subcutaneous tumor growth over the 30 days of the double
dendritic cell injectionmodel (n= 5; *P< 0.05 for sDC to both PBS and uDC groups). (E) Graph indicatingmouse survival (time to cull) in a double
dendritic cell injectionmodel. Black line represents PBS injection; blue line represents uDC and red line represents sDC (n= 5). (F) Numbers of
ova-tetramer+CD8 T cells in the (i) draining popliteal and (ii) non-draining iLNs. Black dots: PBS injectedmice; blue dots: uDC injectedmice; red
dots: sDC injectedmice (n= 5; data points represent individuals). (G) phenotypic characterization of T cell populations in the (i) draining popliteal
and (ii) non-draining iLNs. Black bars: PBS injectedmice; blue bars: unsorted dendritic cell injectedmice; red bars: CCR7+ dendritic cell injected
mice (n= 5). Data are presented asmean± SEM error bars. Statistical analysis was by one-way ANOVA (A, B, D, F) or two-way ANOVA (C, G) with
Bonferroni’s Multiple Comparisons Test, and tumor survival score (E) was assessed using Log-Rank (Mantel Cox) test. *P< 0.05; ***P< 0.0001
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F IGURE 3 CCR7-sorted dendritic cells also enhance immune responses against metastatic tumours. (A) Exemplar histological analyses of
pulmonarymetastatic deposits from PBS injected, Unsorted (mock-sorted) cell injected, and CCR7+ cell injectedmice. (B) Numbers of metastatic
lesions in the lungs of mice as assessed in histological cross-sections of tumor-bearing lungs (n= 10 for PBS and uDC; n= 5 for sDC). (C)
Ova-tetramer positive CD8+ T cell numbers in the popliteal lymph nodes draining the dendritic cell injection site (n= 10 for PBS and uDC; n= 5
for sDC). (D and E). Comparison ofMock sorted (uDC) and CD11c-sorted (CD11c-DC) cells in lungmetastasis model.Whenmice were culled at
the end of the experiment (day 14) there was no reduction in the numbers of tumors detected (CD11c group has significantly more) (D) and no
increases inOva-specific T cells in the draining lymph node (E). Data are presented as individual data points withmean± SEMerror bars. Statistical
analysis was by one-way ANOVA. *P< 0.05; **P< 0.01; ***P< 0.0001
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F IGURE 4 Adapting the chemokine sorting protocol for clinical-grade use. (A) (i) Chemokine-based sorting enrichesmoDCs from being
approximately 55%CCR7+ to in excess of 80%CCR7+ (n= 7). (ii) Yields of approximately 60% are routinely obtained following sorting (n= 4). (iii)
Sorted cells are approximately 90% viable (n= 4; data points represent individuals). (B) Expression of markers of Ag-presenting competence in
CCR7− (grey bars) and CCR7+ (red bars) moDCs (n= 5). (C) (i) Gating strategy showing flow cytometry gates for naïve, effector (TEFF), stem cell
memory (TSCM), and central memory (TCM) T cells. (ii) Quantification of the different T cell populations showing a specific increase in TSCM cells in
response to CCR7+moDC. Data are presented asmean± SEM error bars. Statistical analysis was by one-way ANOVA (Ai) or by two-tailed
Students t-test (Aii, Aiii, Cii). n.s. is not significant. *P< 0.05; **P< 0.01; ***P< 0.0001
allowed to develop to a diameter necessitating animal cull allowing for
a comparison of the relative “survival” of mice receiving the sorted
or unsorted DCs. We observed a 40–50% reduction in tumor growth,
as measured by tumor-diameter, in mice receiving the double pro-
phylactic administration of sorted CCR7+ DC, compared to unsorted
DCs or PBS control (Fig. 2D). This was associated with significantly
increased overall survival of mice receiving sorted DCs compared to
mice receiving either unsorted DCs or PBS control (P = 0.0241). Anal-
ysis of ova-specifc CD8+ T cells indicated elevated numbers in the
footpad-draining pLNs (Fig. 2Fi) but increased numbers were also seen
in the iLN (Fig. 2Fii). Analysis of the specific CD8+ T cell phenotypes in
these tissues (Fig. 2Gi and Gii) revealed that they were predominantly
of an effector phenotype.
Thus double administration of sorted DCs leads to a sustained
increase in tumor Ag-specific T cells over a single injection. This ampli-
fied T cell response is associated with a reduction in tumor develop-
ment and increased “survival.” The Ag-specific T cell phenotype is now
skewed in favor of an effector phenotype suggesting that repeated
doses of CCR7+ DCs lead to the production of a greater number of
effector T cells.
3.4 Sorted DCs display enhanced Ag-specific T
cell reponses in a model of pulmonary metastasis
The B16 model also lends itself to the development of pulmonary
metastases (Supplementary Fig. 2C) following intravenous injection.24
As shown (Fig. 3A), the metastatic deposits that developed in mice
receiving either PBS control or mock sorted, unfractionated cells
or CCR7+ cells were histologically indistinguishable. However, mice
receiving CCR7+ DCs, in contrast to the unsorted cells, developed sig-
nificantly fewer metastatic deposits in the lung. Indeed, we observed
a 50% reduction in metastasis number in mice receiving sorted DCs
compared to unsorted cells or PBS administration. This was asso-
ciated with increased numbers of ova-specific CD8+ T cells in the
pLN (Fig. 3C). These data demonstrate that the CCR7+, compared
to unsorted, DCs can induce an effective immune response against
disseminated, metastatic cancers that leads to reduced metastatic
deposits.
In further investigations using this model, cells sorted based on
expression of CD11c were compared to mock-sorted DC. When mice
were culled at the end of the experiment (day 14) there were no
differences in the numbers of lung tumors or ova-specific T cells in the
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draining lymph node. Thus treatment with this differently sorted pop-
ulation of mature DCs that contains a mixture of CCR7+ and CCR7−
cells does not lead to a reduction in tumor number in this model
(Fig. 3D).
3.5 This approach is translatable to human
therapies
The use of cells in human therapy requires their production under the
most stringentGMPconditions.WegeneratedhumanDCs fromCD14-
purified cells in Xeno-free medium26 the most commonly used in vitro
source of therapeutic DCs. As our CCL19 reagent is chemically synthe-
sized, it can also be produced to the appropriate GMP reagent grade
(Almac Sciences).We sorted humanDCs using the TYTO clinical-grade
cell sorter (www.miltenyibiotec.com/upload/assets/IM0020121.PDF).
Using this clinical-grade disposable cartridge sorter, we were able to
sort, with high efficiency and yield, large numbers of CCR7+ DCs from
a mixed population of human moDCs (Fig. 4Ai and Aii). This differs
from mouse cultures as all cells in the human cultures are DCs (Sup-
plementary Fig. 3), sorting aims to isolate the migration-competent
cells. These CCR7+ sorted cells are viable (Fig. 4Aiii) and, as with their
mouse counterparts, express very high levels of molecules involved in
Ag presentation and stimulation of T cells (Fig. 4B). We next tested
their ability to activate human T cells by incubating CCR7+ andCCR7−
DCs with autologous T cells and EBV Ag for 10 days in vitro and
then assessing T cell phenotypes using flow cytometry. The CCR7+
sorted DCs were capable of significantly enhancing the persistence
of stem cell memory CD8+ T cells in vitro while the CCR7− DC were
not (Fig. 4C). Overall these data demonstrate that the experimental
approach developed for sortingmouse cells using CCL19 is feasible for
humanDC and is of potential direct clinical applicability using identical
reagents.
Wehave therefore shown thatCCR7+-selectedDCs have enhanced
LN homing, Ag presentation, and T cell stimulation capacity that
correlate with increased protection in both the subcutaneous B16
melanoma model and the intravenous model of pulmonary metastasis.
Importantly, our data show the CCR7+ sorted cells are highly enriched
for expression of Zbtb46 and demonstrate superior function to a pop-
ulation of unselected cells containing the same number of CCR7+ cells.
We have shown that separating the CCR7+ cells from the non-CCR7
expressing cells is required for the improved function of the CCR7+
cells – this emphasizes the value of the sorting procedure described
for therapeuticDC therapy. Future studies should concentrate onusing
CCR7+ DC to treat established tumors, for example, following resec-
tion or chemotherapy. In vitro data show CCR7+ DCs, compared to
CCR7− cells, can uniquely prime Ag-specific naïve and memory T cells,
both of which contribute to an antitumor response and are therefore
highlydesirable in a therapeutic context.25 In addition,wedemonstrate
enhanced expression of T cell chemoattractants by sorted DCs sug-
gesting that they may be better equipped to mediate interactions with
T cells upon arrival in the LN.
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